During the last session, Pyxis Oncology Inc. (NASDAQ:PYXS)’s traded shares were 0.5 million. At the end of the trading day, the stock’s price was $2.02, reflecting an intraday loss of -9.01% or -$0.2. The 52-week high for the PYXS share is $19.00, that puts it down -840.59 from that peak though still a striking 0.99% gain since the share price plummeted to a 52-week low of $2.00. The company’s market capitalization is $70.03M, and the average intraday trading volume over the past 10 days was 0.26 million shares, and the average trade volume was 139.17K shares over the past three months.
Pyxis Oncology Inc. (PYXS) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.80. PYXS has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.36.
Pyxis Oncology Inc. (NASDAQ:PYXS) trade information
Pyxis Oncology Inc. (PYXS) registered a -9.01% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -9.01% in intraday trading to $2.02 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is -11.01%, and it has moved by -55.41% in 30 days. The short interest in Pyxis Oncology Inc. (NASDAQ:PYXS) is 0.49 million shares and it means that shorts have 3.59 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.00, which implies an increase of 88.78% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $13.00 and $21.00 respectively. As a result, PYXS is trading at a discount of -939.6% off the target high and -543.56% off the low.
Pyxis Oncology Inc. (PYXS) estimates and forecasts
Statistics show that Pyxis Oncology Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Pyxis Oncology Inc. (PYXS) shares have gone down -83.64% during the last six months, with a year-to-date growth rate more than the industry average at 68.38% against 9.40.
While earnings are projected to return -501.70% in 2022.
Pyxis Oncology Inc. is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Pyxis Oncology Inc. (NASDAQ:PYXS)’s Major holders
Pyxis Oncology Inc. insiders own 14.94% of total outstanding shares while institutional holders control 12.87%, with the float percentage being 15.14%.